Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04186819
Previous Study | Return to List | Next Study

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04186819
Recruitment Status : Recruiting
First Posted : December 5, 2019
Last Update Posted : June 11, 2020
Sponsor:
Collaborator:
Parexel
Information provided by (Responsible Party):
Blue Earth Diagnostics

Brief Summary:
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand in men with newly diagnosed prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: rhPSMA-7.3 (18F) Injection Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 375 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Positron Emission Tomography (PET) Imaging study
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer
Actual Study Start Date : February 12, 2020
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Patients
Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
Drug: rhPSMA-7.3 (18F) Injection
Radioligand for PET CT scanning




Primary Outcome Measures :
  1. Sensitivity of rhPSMA-7.3 (18F) [ Time Frame: 90 days ]

    Sensitivity of rhPSMA-7.3 (18F) PET for detecting pelvic Lymph Node (LN) metastases compared to surgical pathology on a patient level.

    At least one positive pelvic LN (N1) on the PET scan and one positive LN (N1) as determined by histopathology (pN1) on the same side of the pelvis (Left or Right) will be counted a True Positive at the patient level.


  2. Specificity of rhPSMA-7.3 (18F) [ Time Frame: 90 days ]

    Specificity of rhPSMA-7.3 (18F) PET for detecting pelvic Lymph Node (LN) metastases compared to surgical pathology on a patient level.

    At least one positive pelvic LN (N1) on the PET scan and one positive LN (N1) as determined by histopathology (pN1) on the same side of the pelvis (Left or Right) will be counted a True Positive at the patient level.



Secondary Outcome Measures :
  1. Inter-reader agreement of rhPSMA-7.3 (18F) scan interpretation by blinded independent readers. [ Time Frame: 90 days ]
    Kappa statistic for the agreement between blinded independent readers on the interpretation of rhPSMA-7.3 (18F) scans.

  2. Intra-reader agreement of rhPSMA-7.3 (18F) scan interpretation by blinded independent readers. [ Time Frame: 90 days ]
    Kappa statistic for the agreement within blinded independent readers on the interpretation of rhPSMA-7.3 (18F) scans.

  3. Number of participants with treatment-related adverse events as classified by MedDRA [ Time Frame: 90 days ]
    Safety will be assessed from data on the occurrence of one or more treatment-emergent Adverse Events from the time of intravenous administration of 18F-rhPSMA-7.3 throughout the study period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Patients required to have unfavorable intermediate-, high-risk or very high-risk Prostate Cancer
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient is male and aged >18 years old.
  2. Histologically confirmed adenocarcinoma of the prostate.
  3. Patients electing to undergo Radical Prostatectomy (RP) with Pelvic lymph node dissection (PLND).

Exclusion Criteria:

  1. Patients who are planned to have an x-ray contrast agent or other PET radiotracer <24 hours prior to the PET scan.
  2. Patients currently receiving, or with a prior history of, Androgen Deprivation Therapy (ADT).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04186819


Contacts
Layout table for location contacts
Contact: Matthew Cooney +1 216 374 8221 matthew.cooney@parexel.com
Contact: Francesco Paronelli, MD +39 0332 732603 Francesco.Paronelli@parexel.com

Locations
Layout table for location information
United States, California
Tower Urology Recruiting
Los Angeles, California, United States, 90048
Contact: David Josephson         
John Wayne Cancer Institute Recruiting
Santa Monica, California, United States, 90403
Contact: Przemyslaw Twardowski         
United States, Georgia
Emory Healthcare Recruiting
Atlanta, Georgia, United States, 30322
Contact: David Schuster         
United States, Texas
Urology San Antonio Recruiting
San Antonio, Texas, United States, 78229
Contact: Daniel Saltzstein         
United States, Virginia
Virginia Oncology Associates PC Recruiting
Norfolk, Virginia, United States, 23502
Contact: Mark Fleming         
Finland
Turku University Hospital Recruiting
Turku, Finland, FI-20520
Contact: Peter Boström         
Sponsors and Collaborators
Blue Earth Diagnostics
Parexel
Layout table for additonal information
Responsible Party: Blue Earth Diagnostics
ClinicalTrials.gov Identifier: NCT04186819    
Other Study ID Numbers: BED-PSMA-301
First Posted: December 5, 2019    Key Record Dates
Last Update Posted: June 11, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Blue Earth Diagnostics:
Primary Prostate Cancer
Diagnostic
Prostate Specific Membrane Antigen (PSMA)
Positron Emission Tomography (PET) Scan
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases